Electrochemical Synthesis of Self-immolative Methylene Alkoxy Carbamate (MAC) to Facilitate Construction of Antibody–drug Conjugate Linkers with Alcohol-containing Payloads
Publication: Thieme
Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
Publication: Fierce Pharma
Forging the Future: Why Strategic Outsourcing in Biologics is No Longer Optional, It’s Essential for Success
Publication: Fierce Biotechnology
Allometric scaling vs PBPK: when each approach helps in human dose prediction
Compare allometric scaling and PBPK for human dose prediction using in vivo data and mechanistic models. Read more.
From PBPK modeling to first-in-human dose: how predictive DMPK can reduce early clinical risk
Explore how PBPK modeling supports human PK prediction, first-in-human dose selection, and model-informed drug development. Read more.
Engineering Oral Solid Dosage Forms to Enhance Therapeutic Efficiency & Patient Acceptability
Explore how Syngene improves bioavailability, extended release and patient adherence in oral solid dosage forms. Watch the webinar.
BIOSECURE Act 2025 update: what it means for biopharma outsourcing and what to do now
Publication: Pharmaceutical Technology Focus
Clinical development planning in India: From execution hub to strategic trial partner
Explore clinical development planning in India for scalable global trials, integrated execution, and submission-ready evidence. Read more.
Supply chain resilience in multi-continent biopharma manufacturing
See how multi-continent biologics manufacturing supports supply chain resilience through tech transfer, regulatory readiness, and networked delivery. Read more.
Electrochemical Synthesis of Self-immolative Methylene Alkoxy Carbamate (MAC) to Facilitate Construction of Antibody–drug Conjugate Linkers with Alcohol-containing Payloads
Publication: Thieme